

Sheppard Mullin Advises \$200M Life Sciences SPAC IPO

03.08.2022

Sheppard Mullin advised Valuence Merger Corp. I (“Valuence”) in connection with the initial public offering of 20,000,000 units of Valuence Merger Corp. I, for gross proceeds of \$200 million. The units were listed on the Nasdaq Capital Market under the symbol “VMCAU.” Valuence Merger Corp. I is a newly incorporated special purpose acquisition company (SPAC) whose business purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The focus of Valuence is to identify, merge with, and partner with a business in Asia (excluding China, Hong Kong, and Macau) with a particular focus on breakthrough technology in life sciences and/or sustainable technology.

The Sheppard Mullin deal team included partners Paul Kim in Seoul, Richard Friedman, Soyun Park and Niya Tang in New York, and Jason Schendel in Silicon Valley; special counsel Sean Reid in New York; and associate Emily Mastoloni in New York.

[Click here to read the press release.](#)

Attorneys

Richard A. Friedman

Paul J. Kim

Emily Mastoloni

Jason R. Schendel

Practice Areas

Capital Markets

Corporate

Korea

Industries

Life Sciences